Best Electric Utility Companies For 2014

NEW YORK (TheStreet) -- Trina Solar (TSL) stock is soaring in pre-market trading after the company reported better-than-expected earnings in its first quarter. 

Before market open, shares had spiked 8.1% to $11.20. 

Over the three months to March, the company earned 37 cents a share, 34 cents higher than analysts surveyed by Thomson Reuters expected. However, revenue of $444.8 million was under an estimated $452.55 million.

Must Read: Warren Buffett's 25 Favorite Stocks  STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreet Ratings team rates TRINA SOLAR LTD as a Hold with a ratings score of C-. TheStreet Ratings Team has this to say about their recommendation: "We rate TRINA SOLAR LTD (TSL) a HOLD. The primary factors that have impacted our rating are mixed -- some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and poor profit margins." You can view the full analysis from the report here: TSL Ratings Report STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Hot Energy Companies To Buy For 2015: Twin Butte Energy Ltd (TBTEF.PK)

Twin Butte Energy Ltd. (Twin Butte) is a Canada-based junior oil and gas exploration and production company. The Company is engaged in the acquisition of, exploration for and the development and production of petroleum and natural gas properties in Western Canada. During the year ended December 31, 2011, it drilled a total of 125 (80.9 net) wells. Its Frog Lake property is located approximately 75 kilometers northwest of Lloydminster with lands. Its Freemont area is located 60 kilometers southeast of Lloydminster. During 2011, Twin Butte drilled 11 gross wells in Plains region. Production from its west central Alberta region was approximately 1,545 barrels of oil equivalent per day during 2011. Production from its Deep Basin region was approximately 593 barrels of oil equivalent per day during 2011. Effective September 30, 2013, the Company disposed a non-core, west central Alberta, gas asset. In November 2013, the Company acquired Black Shire Energy Inc. Advisors' Opinion:

• [By MLP Trader]

  Here are the current top five companies in the list:

  CompanySymbolEV/BOEPD/NetbackPrice/NAVEV/DACFPinecrest(PNCGF.PK)53564%4.0XLightstream(LSTMF.PK)131753%4.5XNovus(NOVUF.PK)133290%4.1XZargon(ZARFF.PK)138664%5.6XTwin Butte(TBTEF.PK)155885%5.5X

  Of the larger companies, one that remains obstinately near the top of the list is Lightstream . Lightstream trades at 40% of its book value and a whopping 13.4% yield.

Best Electric Utility Companies For 2014: Woolworths Ltd (WOW)

Woolworths Limited is an Australia-based company. The Company operates in five segments: Australian Food and Liquor, New Zealand Supermarkets, Petrol, BIG W and Hotels. Australian Food and Liquor segment is engaged in the procurement of food and liquor and products for resale to customers in Australia. New Zealand Supermarkets segment is engaged in the procurement of food and liquor and products for resale to customers in New Zealand. Petrol segment is engaged in the procurement of petroleum products for resale to customers in Australia. BIG W segment is engaged procurement of discount general merchandise products for resale to customers in Australia. Hotels segment is engaged in the provision of leisure and hospitality services, including food and alcohol, accommodation, entertainment and gaming. Advisors' Opinion:

• [By Jonathan Burgos]

  Woolworths Ltd. (WOW) dropped 1.6 percent to A$33.22 after Australia�� largest retailer said challenging economic condition were evident in the second quarter.

Best Electric Utility Companies For 2014: Fast Retailing Co Ltd (FRCOF)

FAST RETAILING CO., LTD. is a Japan-based holding company primarily engaged in the clothing business. The Company operates in three business segments. The UNIQLO segment is engaged in the sale of casual clothing such as men's, women's, children's and babies' clothing, as well as other goods in domestic market and overseas markets under the brand name of UNIQLO. The Global Brand segment is engaged in the planning, manufacture and sale of clothing under the brands of COMPTOIR DES COTONNIERS, PRINCESSE TAM.TAM, Theory, Helmut Lang, PLST and others in domestic and overseas markets. The Others segment is involved in the leasing of real estate and others. As of August 31, 2012, the Company had 91 consolidated subsidiaries and six non-consolidated subsidiaries. In December, 2012, it acquired a 80.1% stake in United States-based J Brand Holdings, LLC. In September 2013, it established a wholly owned subsidiary, J Brand Japan Co., Ltd. Advisors' Opinion:

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- Japanese stocks weakened in early Thursday trading as the yen rose and Wall Street ended mixed, with the Nikkei Stock Average (JP:NIK) falling 1.2% to 15,929.74 after a 1.9% advance a day earlier. With the yen (USDJPY) slightly firmer than in the previous session, some investors sold currency-sensitive exporters, with Fanuc Corp. (JP:6954) (FANUF) down 2%, Kyocera Corp. (JP:6971) (KYOCF) off 1.9%, and Fujitsu Ltd. (JP:6702) (FJTSY) losing 2.3%. News that China would lift a ban on some sales of videogame consoles had sent shares of Nintendo Co. (JP:7974) (NTDOF) shooting 11% higher on Wednesday, but apparent profit-taking sent the stock down 4.2% in early Thursday action. Shares of rival Sony Corp. (JP:6758) (SNE) , however, followed with a 4% rise, also possibly buoyed by a Nikkei Asian Review report that it was planning a "smartphone offensive" in the U.S. and China. Canon Inc. (JP:7751) (CAJ) fell 2% on a separate Nikkei report that the company's 2013 operating profit would miss forecasts. Toshiba Corp. (JP:6502) (TOSYY)

Best Electric Utility Companies For 2014: Inovio Pharmaceuticals Inc (INO)

Inovio Pharmaceuticals, Inc., incorporated on June 29, 1983, is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. Its clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. Its partners and collaborators include University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (PATH/MVI), National Institute of Allergy and Infectious Diseases (NIAID), Merck, ChronTech, University of Southampton, United States Military HIV Research Program (USMHRP), the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and HIV Vaccines Trial Network (HVTN). As of December 31, 2011 it owned 16.1% interest in VGX Int��.

Inovio�� Solution

The Company�� synthetic vaccine platform consists of its SynCon vaccine design process and electroporation delivery technology. It has developed a preclinical and clinical stage pipeline of vaccines. The Company�� synthetic vaccines are designed to prevent a disease (prophylactic vaccines) or treat an existing disease (therapeutic vaccines). Its synthetic vaccine consists of a deoxyribonucleic acid (DNA) plasmid encoding a selected antigen! (s), which is introduced into cells of humans or animals with the purpose of evoking an immune response to the encoded antigen. The Company�� synthetic vaccines are designed to generate specific antibody and/or T-cell responses.

The Company�� SynCon technology provides processes that employ bioinformatics, which combine extensive genetic data and sophisticated algorithms. Its design process uses the genetic make-up of a common antigen(s) from multiple strains of a virus within a viral sub-type or taxonomic group (family) of pathogens, such as HIV, hepatitis C virus (HCV), human papillomavirus (HPV), influenza and other diseases to synthetically create a new antigen for the desired pathogen target that does not exist in nature. Its synthetic vaccine candidates are being delivered into cells of the body using its electroporation (EP) DNA delivery technology.

Cancer Synthetic Vaccines

The Company has two broad types of cancer vaccines: preventive (or prophylactic) vaccines, which are intended to prevent cancer from developing in healthy people, and treatment (or therapeutic) vaccines, which are intended to treat an existing cancer by strengthening the body�� natural defenses against the cancer. Two types of cancer preventive vaccines are available in the United States. The United States Food and Drug Administration (the FDA) has approved two vaccines, Gardasil and Cervarix that protect against infection by the two types of HPV-types 16 and 18-that cause approximately 70% of all cases of cervical cancer worldwide. In addition, Gardasil protects against infection by two additional HPV types, 6 and 11, which are responsible for about 90% of all cases of genital warts in males and females but do not cause cervical cancer.

Cervarix manufactured by GlaxoSmithKline, is composed of virus-like particles (VLPs) made with proteins from HPV types 16 and 18. Cervarix is approved for use in females��ages 10 to 25 for the prevention of cervical cancer caused by! HPV type! s 16 and 18. Gardasil manufactured by Merck, is approved for use in females for the prevention of cervical cancer, and some vulvar and vaginal cancers, caused by HPV types 16 and 18 and for use in males and females for the prevention of genital warts caused by HPV types 6 and 11. The vaccine is approved for these uses in females and males ages 9 to 26. The FDA has also approved a cancer preventive vaccine that protects against hepatitis B virus (HBV) infection.

Inovio�� VGX-3100 is designed to raise immune responses against the E6 and E7 genes of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into cancerous cells. In March 2011, it initiated a randomized, double-blind Phase II study of VGX-3100 delivered using the CELLECTRA intramuscular electroporation device in women with HPV Type 16 or 18 and diagnosed with, but not yet treated for, cervical intraepithelial neoplasia (CIN) 2/3. The study is designed to enroll 148 subjects. In January 2011, it announced the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of its SynCon vaccine for prostate cancer targeting two antigens, prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA).

In January 2011, the Company announced the regulatory approval of a Phase II clinical trial (WIN Trial) to treat leukemia utilizing its new ELGEN 1000 automated vaccine delivery device. The single dose level, Phase II study, called WT1 immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation. Cancer Vaccines encodes for hTERT, an antigen related to non-small cell lung, breast and prostate cancers. The vaccine is delivered using its electroporation delivery technology.

Infectious Disease Synthetic Vaccines

In Marc! h 2011, the Company announced the initiation of a follow-on open label, single dose Phase II clinical study in collaboration with ChronTech of the ChronVac-C HCV DNA vaccine delivered using its electroporation technology in treatment naive HCV infected individuals. Its HIV vaccines consist of candidates for HIV prevention, as well as therapy or treatment. PENNVAX-B is designed to target HIV clade B (most commonly found in the United States, North America, Australia and the European Union (EU). PENNVAX-G is designed to target HIV clades A, C and D, which are more commonly found in Asia, Africa, Russia and South America. This Phase I clinical study of PENNVAX-B (HVTN-080) vaccinated 48 healthy, HIV-negative volunteers to assess safety and levels of immune responses generated by Inovio�� PENNVAX-B vaccine delivered with its CELLECTRA electroporation device. PENNVAX-B is a SynCon vaccine that targets HIV gag, pol, and env proteins.

The Company�� VGX-3400X targets H5N1. The vaccine consists of three distinct DNA plasmids coded for a consensus hemagglutinin (HA) antigen derived from different H5N1 virus strains; a consensus neuraminidase (NA) antigen derived from different N1 sequences; and a consensus nucleoprotein (NP) fused to a small portion of the m2 protein (m2E) based on a broader cross-section of influenza viruses in addition to H5N1 and H1N1. Conventional vaccines are strain-specific and have limited ability to protect against genetic shifts in the influenza strains they target. They are therefore modified annually in anticipation of the next flu season�� new strain(s). It is focused on developing DNA-based influenza vaccines able to provide broad protection against known as well as newly emerging, unknown seasonal and pandemic influenza strains.

Animal Health/Veterinary

VGX Animal Health, Inc. (VGX AH), a majority-owned subsidiary, has licensed LifeTide, a plasmid-based growth hormone releasing hormone (GHRH) technology for swine. LifeTide is one of onl! y four DN! A-based treatments approved for use in animals and is the only DNA-based agent delivered using electroporation that has been granted marketing approval (Australia). VGX AH is also developing a GHRH-based treatment for cancer and anemia in dogs and cats. It is developing a synthetic vaccine for foot-and-mouth disease (FMD) administered by its vaccine delivery technology. The FMD virus is one of the most infectious diseases affecting farm animals, including cattle, swine, sheep and goats, and is a serious threat to global food safety.

The Company competes with Crucell N.V, Sanofi-Aventis, Novartis, Inc., GlaxoSmithKline plc, Merck, Pfizer, AstraZeneca, Inc., Novartis, Inc., MedImmune and CSL.

Advisors' Opinion:

• [By Roberto Pedone]

  Another biotechnology player that insiders are jumping into here is Inovio Pharmaceuticals (INO), which discovers, develops, and develops synthetic vaccines and immune therapies focusing on cancers and infectious diseases. Insiders are buying this stock into notable weakness, since shares are off by 17.4% so far in 2014.

  Inovio Pharmaceuticals has a market cap of $578 million and an enterprise value of $415 million. This stock trades at a premium valuation, with a price-to-sales of 30.15 and a price-to-book of 4.30. Its estimated growth rate for this year is 56.9%, and for next year it's pegged at -43.5%. This is a cash-rich company, since the total cash position on its balance sheet is $108.86 million and its total debt is zero.

  The CEO just bought 250,000 shares, or about $2.26 million worth of stock, at $9.05 per share.

  From a technical perspective, INO is currently trending below both its 50-day and 200-day moving averages, which is bearish. This stock has been downtrending badly for the last few weeks, with shares moving lower from its high of $14.20 to its recent low of $8.60 a share. During that downtrend, shares of INO have been consistently making lower highs and lower lows, which is bearish technical price action. Shares of INO have now started to explode higher off that $8.60 low and it's quickly approaching a big breakout trade.

  If you're in the bull camp on INO, then I would look for long-biased trades as long as this stock is trending above Wednesday's intraday low of $8.92 or above that recent low of $8.60 and then once it breaks out above both its 50-day at $10.11 and its 200-day at $10.24 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.87 million shares. If that breakout hits soon, then INO will set up to re-test or possibly take out its next major overhead resistance levels at $11 to $11.50, or even $12 to $12.5

Best Electric Utility Companies For 2014: Ryanair (RYAAY)

Ryanair Holdings plc (Ryanair Holdings), incorporated in 1996, is a holding company for Ryanair Limited (Ryanair). Ryanair operates a low-cost, scheduled-passenger airline serving short-haul, point-to-point routes between Ireland, the United Kingdom, Continental Europe, and Morocco. As of June 30, 2012, the Company offered approximately over 1,500 scheduled short-haul flights per day serving approximately 160 airports largely throughout Europe with an operating fleet of 294 aircraft flying approximately 1,500 routes. Ryanair sells seats on a one-way basis. The Company also holds a 29.8% interest in Aer Lingus Group plc. As of June 30, 2012, Ryanair�� operating fleet was composed of 294 Boeing 737-800 aircraft, each having 189 seats. Ryanair�� fleet totaled 294 Boeing 737-800s at March 31, 2012. As of June 30, 2012, Ryanair owned and operated four Boeing 737-800 full flight simulators for pilot training. Ryanair provides ancillary services and engages in other activities connected with its core air passenger service, including non-flight scheduled services, Internet-related services, and the in-flight sale of beverages, food, and merchandise. As part of its non-flight scheduled and Internet-related services Ryanair incentivizes ground service providers at airports it serves to levy correct excess baggage charges for any baggage, which exceeds Ryanair�� published baggage allowances. Excess baggage charges are recorded as non-flight scheduled revenue. Ryanair distributes accommodation services and travel insurance through its Website. For hotel services, Ryanair has a contract with Hotelscombined PTY Ltd. (Hotelscombined), which operates a price comparison Website, pursuant to which Hotelscombined handles all aspects of such services marketed through Ryanair�� Website and pays a fee to Ryanair. Ryanair also has contracts with other accommodation providers that enable Ryanair to offer hostel, bed-and-breakfast, guesthouse, villa and apartment accommodation to its customers. In addition Ryanair has a contract with Hertz, pursuant to which Hertz handles all car rental services marketed through Ryanair�� Website or telephone reservation system. Ryanair also sells bus and rail tickets onboard its aircraft and through its Website. Ryanair also sells attractions and activities on its Website. Ryanair sells gift vouchers on its Website, which are also redeemable online. The Company has an contract with Webloyalty International Ltd, which offers Ryanair�� customers who have a United Kingdom, German or French billing address a retail discount and cash-back program. Ryanair has agreements, pursuant to which the Company promotes Ryanair-branded credit cards issued by MBNA, GE Money, Access Prepaid and Banco Santander on its Internet site. The MBNA agreement relates to Irish residents only, the GE Money agreement relates to Swedish and Polish residents only and the Banco Santander agreement relates to United Kingdom residents only. During the fiscal year ended March 31, 2012, Ryanair rolled out handheld Electronic Point of Sale (EPOS) devices across its route network. These EPOS devices replaced manual and paper based systems on board the aircraft. The EPOS device enables cabin crew to sell and record their on-board sales transactions. The EPOS device also issues bus and rail tickets and tickets for tourist attractions. The Company also offers reserved seating in twenty-one extra legroom seats on each aircraft for a fee on certain routes. Ryanair provides its own aircraft and passenger handling and ticketing services at Dublin Airport. Third parties provide these services to Ryanair at other airports it serves. Servisair plc provides Ryanair�� ticketing, passenger and aircraft handling, and ground handling services at airports in Ireland and the United Kingdom(excluding London (Stansted) Airport where these services are provided by Swissport Ltd.), while similar services in continental Europe are provided by the local airport authorities, either directly or through sub-contractors. Advisors' Opinion:

• [By Jon C. Ogg]

  Ryanair Holdings PLC (NASDAQ: RYAAY) was downgraded to Neutral from Buy at UBS.

  Verizon Communications Inc. (NYSE: VZ) was reiterated as Buy and on the Focus List with a $59 price target at Argus, and it was raised to Outperform at RW Baird.

• [By GURUFOCUS]

  In the world of publicly-owned businesses, we try to invest with the same sort of individuals. In our opinion, Michael O'Leary, Ryanair's Chairman and CEO, is one such example of a talented, driven executive. Michael was born on a farm in Ireland, the second oldest of six siblings. Although his beginnings were not remarkable, Michael figured out how to get the best education he could by attending the best schools he could. After attending a Jesuit boarding school as a young boy, he graduated from Trinity College with an accounting degree; began his career working for KPMG, a large public accounting firm; and, soon afterwards, became a financial advisor to Tony Ryan, Ryanair's founder. In 1986, Michael was hired to work for Ryan and initially advised him to close the airline immediately since it was losing so much money! In 1989, when Ryanair (RYAAY) was on the brink of insolvency, Ryan offered Michael the job of Deputy CEO of the airline and in 1994 as its CEO. Michael accepted, on the condition that if he couldn't make it profitable, he would be allowed to shut it down! He also chose to work for a percentage of profits rather than for a salary from the money losing business.

• [By Luke Jacobi]

  Ryanair Holdings plc (NASDAQ: RYAAY) shares were up nearly 6.97 percent into the close to $54.53 after the company reported full-year results. Ryanair's net profit for the year ended March 31 slipped to 522.8 million euros ($716 million), versus a year-ago profit of 569.3 million euros.

Best Electric Utility Companies For 2014: Teekay Offshore Partners L.P.(TOO)

Teekay Offshore Partners L.P. provides marine transportation, oil production, and storage services to the offshore oil industry. It operates shuttle tankers, floating storage and offtake (FSO) units, and conventional crude oil tankers, as well as floating production, storage, and offloading (FPSO) units. As of June 30, 2011, its fleet consisted of 40 shuttle tankers, including 5 chartered-in vessels and 4 committed newbuildings; 2 FPSO units; 5 FSO units; and 10 conventional oil tankers. The company primarily serves energy and oil service companies, and their affiliates. Teekay Offshore GP L.L.C. serves as the general partner of the company. The company was founded in 2006 and is headquartered in Hamilton, Bermuda.

Advisors' Opinion:

• [By Kashafa Investment Research]

  Teekay Offshore Partners L.P. (TOO) is the largest owner in the shuttle tanker market with 33 shuttle tankers and one newbuilds on order. Through this, the company owns more than 50% of the world's shuttle tanker fleet based on total tonnage.